Skip to main content

Advertisement

Table 3 Results of the fixed-effect direct, Bucher indirect and NMA comparisons

From: A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy

Comparison HbA1c Weight (kg) Hypoglycaemia
NMA (95% CrI) Direct/Bucher indirect (95% CI) NMA (95% CrI) Direct/Bucher indirect (95% CI) NMA (95% CrI) Direct/Bucher indirect (95% CI)
  WMD v placebo Direct comparison WMD v placebo Direct comparison OR v placebo Direct comparison
DPP-4 v placebo -0.56 (-0.70, -0.41)† -0.56 (-0.70, -0.41)* 0.57 (0.09, 1.06)† 0.57 (0.09, 1.05)* 1.87 (0.82, 4.72) 1.8 (0.78, 4.17)
GLP-1 v placebo -0.80 (-1.04, -0.56)† -0.79 (-1.02, -0.55)* -0.65 (-1.37, 0.07) -0.65 (-1.37, 0.07) 10.89 (4.24, 38.28)† 10.05 (3.60, 28.06)*
SGLT2 v placebo -0.69 (-0.86, -0.52)† -0.69 (-0.86, -0.52)* -1.54 (-2.16, -0.92)† -1.54 (-2.16, -0.92)* 1.75 (0.67, 4.89) 1.71 (0.66, 4.48)
  WMD head-to-head Bucher indirect comparison WMD head-to-head Bucher indirect comparison OR head-to-head Bucher indirect comparison
GLP-1 v DPP-4 -0.24 (-0.52, 0.04) -0.23 (-0.50, 0.04) -1.23 (-2.09, -0.36)† -1.22 (-2.09, -0.35)* 5.89 (1.56, 26.06)† 5.58 (1.49, 20.99)*
SGLT2 v DPP-4 -0.13 (-0.35, 0.09) -0.13 (-0.35, 0.09) -2.11 (-2.90, -1.33)† -2.11(-2.90, -1.33)* 0.94 (0.25, 3.50) 0.95 (0.27, 3.37)
SGLT2 v GLP-1 0.11 (-0.18, 0.40) 0.10 (-0.19, 0.39) -0.89 (-1.84, 0.07) -0.89 (-1.84, 0.06) 0.16 (0.03, 0.65)† 0.17 (0.04, 0.69)*
  WMD v baseline WMD v baseline Probability of hypoglycaemia
placebo 0.05 (-0.10, 0.20) N/A -0.48 (-0.78, -0.18)† N/A 3.99% (2.30%, 6.85%) N/A
DPP-4 -0.51 (-0.72, -0.30)† N/A 0.09 (-0.47, 0.66) N/A 7.23% (2.75%, 18.67%) N/A
GLP-1 -0.75 (-1.03, -0.47)† N/A -1.13 (-1.91, -0.35)† N/A 31.38% (13.00%, 64.10%) N/A
SGLT2 -0.64 (-0.87, -0.42)† N/A -2.02 (-2.71, -1.33)† N/A 6.81% (2.33%, 19.04%) N/A
  Model parameter results  
DIC (WinBUGs) -10.36 N/A 13.07 N/A 72.301 N/A
Average resdev 1.37 N/A 1.14 N/A 2.25 N/A
  1. *Statistically significant result (p < 0.05); †statistically significant based on 95% CrI; CI, confidence interval; CrI, credible interval; DIC, deviance information criterion; DPP-4, dipeptidyl peptidase-4 inhibitors; GLP-1, glucagon-like peptide-1 analogues; OR, odds ratio; NMA, network meta-analysis; resdev, residual deviance; SGLT2, sodium glucose co-transporter 2 inhibitors; WMD, weighted mean difference.